AbCellera Biologics: UBS initiates coverage with buy rating and $18 target price
ABCL•UBS initiated coverage of AbCellera Biologics with a buy rating and an $18 target price.
Related News
Spyre Therapeutics gets UBS buy rating with $120 target price
SYRE•
Nasdaq trade halt continues; volatility trading pause at 9:53 a.m.
NXGL•
Deals of the day: Mergers and acquisitions
AMZN•
Nasdaq trading halt: volatility trading pause at 10:19 a.m.
MNDR•
L3Harris expands solid rocket motor production with new 60,000-sq-ft Camden, Arkansas facility
LHX•